Equity Research is published in the framework of the Tel Aviv Stock Exchange (TASE) Analysis Program
TEL AVIV, Israel, Feb. 6, 2018 /PRNewswire/ -- The TASE analysis project was launched in 2016 in order to raise investors' level of knowledge of TASE listed technology and biotech companies, and the markets in which they operate. This enables the creation of appropriate
In order to maintain professional, independent and unbiased analysis, the companies signed an agreement with the TASE to receive the analysis services for an obligatory period of two years. The companies cannot withdraw from the project during this period. The analysis is funded by the companies surveyed with funding from the Chief Scientist and the TASE.
Summary of Highlights
About the Company
Israeli holdings firm DNA Biomedical Solutions Ltd. ('DNA' or 'DNA Biomed') has two key holdings, respective 35% and 40% stakes (both fully diluted) in biomedical companies - Entera Bio and BeamMed. Entera Bio is a drug development company, founded in 2009 by DNA and Oramed, the latter from whom it has licensed a unique drug delivery platform for oral administration of pharmaceutical active large molecule proteins that are nowadays injected. Entera is conducting clinical trials for two candidate drugs treating three indications: hypoparathyroidism, osteoporosis and non-union fractures. BeamMed, and its global subsidiaries, are medical device companies that deliver an ultrasound based screening solution for determining a patient's risk of developing osteoporosis, with unique additional product features, please click here.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion
For further information, please contact:
Kristi Cekani Corporate Communications - Frost & Sullivan, EuropeP: +39.02.4851.6133E: Kristi.firstname.lastname@example.org http://www.frost.com
View original content:http://www.prnewswire.com/news-releases/frost--sullivan-publishes-update-coverage-report-on-dna-biomedical-solutions-ltd-enteras-unsuccessful-nasdaq-ipo-is-not-expected-to-have-a-significant-impact-on-its-clinical-plans-price-target-affected-by-a-change-in-the-exch-300593978.html
SOURCE Frost & Sullivan
Subscribe to our Free Newsletters!